These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29687658)

  • 21. Autofluorescence of Skin Advanced Glycation End Products: Marker of Metabolic Memory in Elderly Population.
    Rajaobelina K; Cougnard-Gregoire A; Delcourt C; Gin H; Barberger-Gateau P; Rigalleau V
    J Gerontol A Biol Sci Med Sci; 2015 Jul; 70(7):841-6. PubMed ID: 25589479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study.
    Arnold SV; Khunti K; Tang F; Chen H; Cid-Ruzafa J; Cooper A; Fenici P; Gomes MB; Hammar N; Ji L; Saraiva GL; Medina J; Nicolucci A; Ramirez L; Rathmann W; Shestakova MV; Shimomura I; Surmont F; Vora J; Watada H; Kosiborod M
    Am Heart J; 2022 Jan; 243():232-239. PubMed ID: 34666013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skin advanced glycation end products in HIV infection are increased and predictive of development of cardiovascular events.
    Sprenger HG; Bierman WF; Martes MI; Graaff R; van der Werf TS; Smit AJ
    AIDS; 2017 Jan; 31(2):241-246. PubMed ID: 27763891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in HbA1c during the first six years after the diagnosis of Type 2 diabetes mellitus predict long-term microvascular outcomes.
    Rozing MP; Møller A; Aabenhus R; Siersma V; Rasmussen K; Køster-Rasmussen R
    PLoS One; 2019; 14(11):e0225230. PubMed ID: 31774849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relation Between Different Measures of Glycemic Exposure and Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes Mellitus: An Observational Cohort Study.
    van Wijngaarden RPT; Overbeek JA; Heintjes EM; Schubert A; Diels J; Straatman H; Steyerberg EW; Herings RMC
    Diabetes Ther; 2017 Oct; 8(5):1097-1109. PubMed ID: 28921256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skin autofluorescence as a measure of advanced glycation end products deposition predicts 5-year amputation in patients with peripheral artery disease.
    de Vos LC; Boersema J; Mulder DJ; Smit AJ; Zeebregts CJ; Lefrandt JD
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1532-7. PubMed ID: 25882066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Self-reported Physical Activity and Skin Autofluorescence, a Marker of Tissue Accumulation of Advanced Glycation End Products in Adults With Type 1 Diabetes: A Cross-sectional Study.
    Duda-Sobczak A; Falkowski B; Araszkiewicz A; Zozulinska-Ziolkiewicz D
    Clin Ther; 2018 Jun; 40(6):872-880. PubMed ID: 29567299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The skin autofluorescence of advanced glycation end-products relates to the development of foot ulcers in type 2 diabetes: A longitudinal observational study.
    Borderie G; Foussard N; Larroumet A; Blanco L; Barbet-Massin MA; Ducos C; Rami-Arab L; Domenge F; Mohammedi K; Ducasse E; Caradu C; Rigalleau V
    J Diabetes Complications; 2023 Oct; 37(10):108595. PubMed ID: 37647711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review.
    Bos DC; de Ranitz-Greven WL; de Valk HW
    Diabetes Technol Ther; 2011 Jul; 13(7):773-9. PubMed ID: 21510765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up.
    Adamsson Eryd S; Svensson AM; Franzén S; Eliasson B; Nilsson PM; Gudbjörnsdottir S
    Diabet Med; 2017 Mar; 34(3):411-418. PubMed ID: 27647178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Skin autofluorescence of Advanced Glycation End-products and mortality in older adults: The roles of chronic kidney disease and diabetes.
    Majchrzak C; Cougnard-Gregoire A; Le-Goff M; Féart C; Delcourt C; Reydit M; Helmer C; Rigalleau V
    Nutr Metab Cardiovasc Dis; 2022 Nov; 32(11):2526-2533. PubMed ID: 36064683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progression of skin autofluorescence of AGEs over 4 years in patients with type 1 diabetes.
    Rajaobelina K; Helmer C; Vélayoudom-Céphise FL; Nov S; Farges B; Pupier E; Blanco L; Hugo M; Gin H; Rigalleau V
    Diabetes Metab Res Rev; 2017 Oct; 33(7):. PubMed ID: 28719154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skin autofluorescence and the complexity of complications in patients with type 2 diabetes mellitus: a cross-sectional study.
    Wang X; Zhao X; Lian T; Wei J; Yue W; Zhang S; Chen Q
    BMC Endocr Disord; 2021 Apr; 21(1):58. PubMed ID: 33794864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between dietary and skin advanced glycation end products: the Rotterdam Study.
    Chen J; Waqas K; Tan RC; Voortman T; Ikram MA; Nijsten TEC; de Groot LCPGM; Uitterlinden AG; Zillikens MC
    Am J Clin Nutr; 2020 Jul; 112(1):129-137. PubMed ID: 32453418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Skin autofluorescence is associated with progression of kidney disease in type 2 diabetes: A prospective cohort study from the Hong Kong diabetes biobank.
    Jin Q; Lau ES; Luk AO; Ozaki R; Chow EY; So T; Yeung T; Loo KM; Lim CK; Kong AP; ; So WY; Jenkins AJ; Chan JC; Ma RC
    Nutr Metab Cardiovasc Dis; 2022 Feb; 32(2):436-446. PubMed ID: 34895800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Skin autofluorescence and complications of diabetes: does ethnic background or skin color matter?
    Ahdi M; Gerdes VE; Graaff R; Kuipers S; Smit AJ; Meesters EW
    Diabetes Technol Ther; 2015 Feb; 17(2):88-95. PubMed ID: 25562390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skin Autofluorescence - A Non-invasive Measurement for Assessing Cardiovascular Risk and Risk of Diabetes.
    Stirban A; Heinemann L
    Eur Endocrinol; 2014 Aug; 10(2):106-110. PubMed ID: 29872473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular events after a dramatic reduction of HbA1c in hospitalized subjects with type 2 diabetes and high long-term glucose exposure.
    Rigalleau V; Larroumet A; Ducos C; Rigo M; Barbet-Massin MA; Majchrzak C; Mohammedi K; Baillet-Blanco L; Monlun M; Rami-Arab L; Foussard N
    J Diabetes Complications; 2022 Aug; 36(8):108234. PubMed ID: 35752528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
    Konig M; Lamos EM; Stein SA; Davis SN
    Curr Diabetes Rev; 2013 Sep; 9(5):371-81. PubMed ID: 23865412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus.
    Lutgers HL; Gerrits EG; Graaff R; Links TP; Sluiter WJ; Gans RO; Bilo HJ; Smit AJ
    Diabetologia; 2009 May; 52(5):789-97. PubMed ID: 19274450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.